2002
DOI: 10.2174/1381612023393756
|View full text |Cite
|
Sign up to set email alerts
|

Experience with Indium-111 and Yttrium-90-Labeled Somatostatin Analogs

Abstract: The high level expression of somatostatin receptors (SSTR) on various tumor cells has provided the molecular basis for successful use of radiolabeled octreotide / lanreotide analogs as tumor tracers in nuclear medicine. Other (nontumoral) potential indications for SSTR scintigraphy are based on an increased lymphocyte binding at sites of inflammatory or immunologic diseases such as thyroid-associated ophthalmology. The vast majority of human tumors seem to over-express the one or the other of five distinct hSS… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
56
0
1

Year Published

2003
2003
2013
2013

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 87 publications
(57 citation statements)
references
References 0 publications
0
56
0
1
Order By: Relevance
“…www.endocrinology-journals.org responses in up to 30% of GEP NETs (De Jong et al 1999, Virgolini et al 2002, Ezziddin et al 2006, Kwekkeboom et al 2008. Alternatively, around 20% of NETs may be identifiable on a metaiodiobenzylguanidine (MIBG) scan.…”
Section: Targeted Radiotherapymentioning
confidence: 99%
“…www.endocrinology-journals.org responses in up to 30% of GEP NETs (De Jong et al 1999, Virgolini et al 2002, Ezziddin et al 2006, Kwekkeboom et al 2008. Alternatively, around 20% of NETs may be identifiable on a metaiodiobenzylguanidine (MIBG) scan.…”
Section: Targeted Radiotherapymentioning
confidence: 99%
“…A limitation, however, is the rather low yield of conversion electrons that are emitted by Indium-111 per Bq, which is 0.050 per Bq·s and 0.083 per Bq·s for the 219 keV and 145 keV electrons, respectively. More recently, data have become available on the use of Yttrium-90 labelled somatostatin analogues (10,11). Yttrium-90 is a pure beta-emitter, with a relative high energy of 935 keV of the electrons emitted.…”
Section: Discussionmentioning
confidence: 99%
“…More recently, the results of 87 patients with NETs (57% had GEP and 16% MTC) treated with a cumulative activity ranging from 7.4 -20.3 GBq were presented; a tumour response was obtained in 28% (5% complete response) with no major adverse effects up to a dose of 5.55 GBq/cycle (121). Other studies also involving the administration of DOTA-D-Phe 1 -Tyr 3 -octreotide in patients with NETs have mainly demonstrated a partial tumour response, while a considerable number showed disease stabilization (122); an overall partial response rate of around 20% has been documented in all these studies with a maximum cumulative dose being relatively less than the maximum tolerable dose (44). A Novartis-sponsored phase II study is currently ongoing to test the efficacy of OctreoTher in patients with a variety of disseminated NETs; it is hoped that the detailed results will be published soon (44,114).…”
Section: Treatment With Radiolabelled Somatostatin Analoguesmentioning
confidence: 98%